Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

European GMP certification awarded to Ajinomoto Althea

Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

3 Sep 2014

First Edition: September 3, 2014

Today's headlines include reports about how insurers and consumers are bracing for round two as the health law's online insurance marketplaces prepare for open enrollment season.

3 Sep 2014

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.

3 Sep 2014

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

3 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

30 Aug 2014

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa.

29 Aug 2014

H. D. Smith announces winners of annual Trading Partners of the Year award

H. D. Smith, among the nation's largest pharmaceutical wholesalers, today announced the winners of its annual Trading Partners of the Year award, honoring select pharmaceutical and health products manufacturers who collaborate actively to grow the industry and advance patient care.

28 Aug 2014

EMIT receives CE-Mark for HypothermX Intravenous Fluid and Blood Warming Devices

EMIT Corporation announced today that it has received CE-Mark for its HypothermX Intravenous Fluid and Blood Warming Devices with sterile fluid paths, allowing for sales expansion into the European and other OUS markets.

28 Aug 2014

TxCell announces five new patents for core technology and ASTrIA platform

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014.

27 Aug 2014

Actavis files ANDA for generic version of Neupro

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.

25 Aug 2014

Dr. John S. Sampalis nominated as finalist in the 2014 EY Entrepreneur Of The Year award

Dr. John S. Sampalis is founder and CEO of JSS Medical Research and one of the world's leading clinical epidemiologists. Dr. Sampalis is nominated as a finalist in this year's 2014 EY Entrepreneur Of The Year in the Québec Health Sciences category.

22 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended June 30, 2014.

15 Aug 2014

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Neovasc Inc. ("Neovasc" or the "Company") today announced financial results for the three months ended March 31, 2014. All results are reported in Canadian dollars unless otherwise stated.

13 Aug 2014

Six Sigma approach in manufacturing industries can improve healthcare for rural communities

By adapting the "Lean Six Sigma" principle of manufacturing to rural hospitals, Indian researchers suggest that patient queues might be shortened by 91 percent while consultation time could be reduced to about a third of the time.

13 Aug 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year.

12 Aug 2014

GOP efforts to become 'party of yes' will likely include 'realistic' proposals to change the health law

In what is emerging as an aggressive strategy for Congressional Republicans, these proposals would likely follow an early and largely symbolic vote to repeal the overhaul. Meanwhile, much is at stake in state-level elections.

12 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Manufacturing News and Research

Further Reading

European GMP certification awarded to Ajinomoto Althea

First Edition: September 3, 2014

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Pfenex reports total revenue of $3.3 million for second quarter 2014

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

H. D. Smith announces winners of annual Trading Partners of the Year award

EMIT receives CE-Mark for HypothermX Intravenous Fluid and Blood Warming Devices

TxCell announces five new patents for core technology and ASTrIA platform

Actavis files ANDA for generic version of Neupro

Dr. John S. Sampalis nominated as finalist in the 2014 EY Entrepreneur Of The Year award

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Six Sigma approach in manufacturing industries can improve healthcare for rural communities

GenVec reports net loss of $1.7 million for second quarter 2014

GOP efforts to become 'party of yes' will likely include 'realistic' proposals to change the health law

Omeros reports net loss of $18 million for second quarter 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest Life Science News